Место пробиотиков и пребиотиков в терапии заболеваний желудочно-кишечного тракта


Авдеев В.Г.

Кафедра внутренних болезней МГУ им. М.В. Ломоносова, Москва
Обсуждается значение пребиотиков и пробиотиков в лечении заболеваний желудочно-кишечного тракта. Дан обзор результатов экспериментальных и клинических исследований, проведенных в последние годы, позволивших значительно расширить представления о механизмах влияния пробиотиков и пребиотиков на организм и более обоснованно назначать их при различных патологических состояниях.

Литература


1. Парфенов А.И. Энтерология М., 2002. 744 с.


2. Ткаченко Е.И. Питание, эндоэкология человека, здоровье, болезни. Современный взгляд на проблему их взаимосвязей // Терапевтический архив. 2004. Т. 76. № 2. С. 67–71.


3. Volker Mai, Draganov PV. Recent advances and remaining gaps in our knowledge of associations between gut microbiota and human health. World J Gastroenterol 2009;15(1):81–85.


4. Парфенов А.И. Постинфекционный синдром раздраженного кишечника: вопрос лечения и профилактики // Consilium med. 2001. Т. 4. № 6. С. 298–300.


5. Мехтиев С.Н., Гриневич В.Б., Захаренко С.М. Дисбактериоз кишечника. Вопросы и ответы. М. ГОУ ВУНМЦ МЗ и СР РФ, 2006. 63 с.


6. Forestier C, Guelon D, Cluytens V, et al. Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, doubleblind, placebo-controlled pilot study in intensive care unit patients. Crit Care 2008; 12(3): 69–70.


7. Kalliomaki M, et al. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebocontrolled trial. J Allergy Clin Immunol. 2007;119(4):1019–21.


8. Lodinova-Zadnikova R, et al. Influence of oral colonization with probiotic E. coli strain after birth on frequency of recurrent infections, allergy and development of some immunologic parameters. Long-term studies. Ceska Gynekol 2004;69(1):91–7.


9. Abrahamsson TR, et al. Probiotics in prevention of IgE-associated eczema. a doubleblind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007; 119(5):1174–80.


10. Passeron T, et al. Prebiotics and synbiotics. two promising approaches for the treatment of atopic dermatitis in children above 2 years. Allergy 2006;61(4):431–37.


11. Shornikova AV, Casas IA, Isolauri E, et al. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 1997;24(4):399–404.


12. Shornikova AV, Casas IA, Mykkänen H, et al. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997;16(12):1103–107.


13. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005;115(1):5–9.


14. Oberhelman RA, Gilman RH, Sheen P, et al. A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. J Pediatrs. 1999;134(1):15–20.


15. Pedone CA, Arnaud CC, Postaire ER, et al. Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int J Clin Pract 2000;54(9):568–71.


16. Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344(8929):1046–9.


17. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutrit 2001; 33(4):17–25.


18. Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutrit 2000; 30(1):54–60.


19. Леонтьева Н.И., Щербаков И.Т., Партин О.С. и др. Применение Хилак форте у больных острыми и хроническими заболеваниями желудочно-кишечного тракта и дисбактериозом кишечника. Материалы IX Российского национального конгресса “Человек и лекарство”. М., 2001. 262 с.


20. Мазанкова Л.Н., Ильина Н.И., Кондракова О.А. и др. Оценка нарушений микробиоценоза при острых кишечных инфекциях у детей и их коррекция // Трудный пациент. 2004. Т. 2. № 9. С. 11–6.


21. Грачева Н.М., Леонтьева Н.И., Щербаков И.Т. и др. Хилак форте в комплексном лечении больных острыми кишечными инфекциями и хроническими заболеваниями желудочно-кишечного тракта с явлениями дисбактериоза // Consilium medicum. 2004. № 1. С. 31–4.


22. D Souza AL, Rajkumar C, Cooke J, et al.: Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ2002;324:1360–1.


23. Пальгова Л.К., Бикебаева А.Ж., Бекбаева А.А. и др. Антибиотикоассоциированные диареи в практике врача и оценка результатов коррекции препаратом Хилак форте // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2002. Т. 12. № 5. 59 с.


24. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003;35:365–67.


25. Seki H, Shiohara M, Matsumura T, et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int 2003;45:86–0.


26. Correa NBO, Peret Filho LA, Penna FJ, et al. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol 2005;39(5):385–9.


27. Ahuja MC, Khamar B. Antibiotic associated diarrhoea: a controlled study comparing plain antibiotic with those containing protected lactobacilli. J Indian Med Assoc 2002;100:334–5.


28. Ushiyama A, Tanaka K, Aiba Y, et al. Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. J Gastroenterol Hepatol 2003;18:986–1.


29. Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003;22:360–6.


30. Cruchet S, Obregon MC, Salazar G, et al. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition 2003;19:716–1.


31. Rayes N, Seehofer D, Hansen S, et al.: Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002;74:123–7.


32. Rayes N, Seehofer D, Muller AR, et al. Influence of probiotics and fibre on the incidence of bacterial infections following major abdominal surgeryresults of a prospective trial. ZGastroenterol 2002;40:869–6.


33. Урсова Н.И., Римарчук Г.В. Опыт лечения функциональных запоров у детей. Материалы конференции педиатров России. Фармакотерапия и фармакогенетика в педиатрии. М., 2000. 168 с.


34. Урсова Н.И. Роль и место пробиотиковв лечении и профилактике различных заболеваний и состояний, обусловленных дисбиотическими нарушениями кишечника. Научныйобзор. М., 2002. 28 с.


35. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoeapredominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895–904.


36. Bazzocchi G, Gionchetti P, Almerigi PF, et al. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 2002;34(2):48–53.


37. Brigidi P, Vitali B, Swennen E, et al. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001;152:735–41.


38. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343–50.


39. Bamba T, Kanauchi O, Andoh A, et al. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 2002;17:818–24.


40. Kanauchi O, Serizawa I, Araki Y, et al. Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol 2003;38:134–41.


41. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635–39.


42. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617–23.


43. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697–98.


44. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 2000;45:1462–64.


45. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56–63.


46. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004;20:1133–41.


47. Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2003;38:409–14.


48. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebocontrolled trial. Gastroenterology 2003; 124:1202–9.


49. Reddy BS, Hamid R, Rao CV. Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition. Carcinogenesis 1997;18:1371–74.


50. Rafter J. Probiotics and colon cancer. Best Pract Res Clin Gastroenterol 2003; 17:849–59.


51. Campbell TC, Hayes JR. The effect of quantity and quality of dietary protein on drug metabolism. Fed Proc 1976;35:2470–74.


52. Guengerich FP. Cytochromes P450, drugs, and diseases. Molecular Intervent 2003; 3:194–204


53. Lang NP, Butler MA, Massengill J, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomark Prevent 1994;3:675–82.


54. Horie H, Zeisig M, Hirayama K, et al. Probiotic mixture decreases DNA adduct formation in colonic epithelium induced by the food mutagen 2-amino-9H-pyrido[2,3-b]indole in a human-flora associated mouse model. Eur J Cancer Prev 2003;12:101–7.


55. Galdeano M, Perdigon G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol 2006;13:219–26.


56. Ponz de Leon M, Roncucci L. Chemoprevention of Colorectal Tumors: Role of Lactulosa and Other Agents. Scand J Gastroenter 1997;32(222):72–75.


57. Solga SF. Probiotics can treat hepatic encephalopathy. Med Hypotheses 2003; 61:307–13.


Похожие статьи


Бионика Медиа